Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease

KM Kew, A Seniukovich - Cochrane Database of Systematic …, 2014 - cochranelibrary.com
Background Inhaled corticosteroids (ICS) are anti‐inflammatory drugs that have proven
benefits for people with worsening symptoms of chronic obstructive pulmonary disease …

[HTML][HTML] Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease

LJ Nannini, CJ Cates, TJ Lasserson… - The Cochrane database …, 2007 - ncbi.nlm.nih.gov
Background Long-acting beta-agonists and inhaled corticosteroids have both been
recommended in guidelines for the treatment of chronic obstructive pulmonary disease …

Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease

LJ Nannini, P Poole, SJ Milan… - Cochrane Database of …, 2013 - cochranelibrary.com
Background Both long‐acting beta 2‐agonists and inhaled corticosteroids have been
recommended in guidelines for the treatment of chronic obstructive pulmonary disease …

Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials

M Yang, Y Du, H Chen, D Jiang, Z Xu - International immunopharmacology, 2019 - Elsevier
Objective Inhaled corticosteroids (ICS) are generally used to treat patients with chronic
obstructive pulmonary disease (COPD) who suffer from repeated exacerbations. Recently, it …

[HTML][HTML] Inhaled corticosteroids and the pneumonia risk in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials

H Chen, J Sun, Q Huang, Y Liu, M Yuan… - Frontiers in …, 2021 - frontiersin.org
Background: Whether all types of inhaled corticosteroids (ICSs) would increase the
pneumonia risk in patients with chronic obstructive pulmonary disease (COPD) remains …

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results

C Crim, PMA Calverley, JA Anderson… - European …, 2009 - Eur Respiratory Soc
Inhaled corticosteroids (ICS) are important in reducing exacerbation frequency associated
with chronic obstructive pulmonary disease (COPD). However, little is known about the risk …

Inhaled corticosteroids versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease

S Spencer, C Karner, CJ Cates… - Cochrane Database of …, 2011 - cochranelibrary.com
Background Long‐acting beta 2‐agonists and inhaled corticosteroids can be used as
maintenance therapy by patients with moderate to severe chronic obstructive pulmonary …

Inhaled corticosteroids in COPD and the risk of serious pneumonia

S Suissa, V Patenaude, F Lapi, P Ernst - Thorax, 2013 - thorax.bmj.com
Background Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in
patients with chronic obstructive pulmonary disease (COPD). It is unclear whether the risk of …

Inhaled corticosteroids in COPD: the clinical evidence

P Ernst, N Saad, S Suissa - European Respiratory Journal, 2015 - Eur Respiratory Soc
In this article, we focus on the scientific evidence from randomised trials supporting
treatment with inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease …

Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease

LJ Nannini, P Poole, SJ Milan… - Cochrane Database …, 2013 - cochranelibrary.com
Background Both long‐acting beta 2‐agonists (LABA) and inhaled corticosteroids (ICS)
have been recommended in guidelines for the treatment of chronic obstructive pulmonary …